Benefits of a predictive computational solutions
Proprietary method, unique know-how
Our expertise in protein-protein interactions and protein modelling to ensure optimized predictions
Full ownership and exclusive right for customer
Prediction report within 2-4 weeks
Deep characterization for high protection
Either predictive in silico data or experimental validations using state-of-the art protein-protein interaction technologies (HTRF, biolayer interferometry…), or both
We accelerate and secure the development of your antibody at early stage
Vincent Puard, PhD
10 years of international experience in academia and private business working with antibodies
Astrid Musnier, PhD
10 years of international experience in research and academia. Expert in protein-protein interaction technologies, co-inventor of the methods
Anne Poupon, PhD
International expert of more than 20 years of research in bioinformatics leading to the invention of our methods. PI at CNRS and co-leader of the BIOS group at INRA Val de Loire
As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.
This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.
MAbSilico is talking at the 6th Antibody Industrial Symposium. June 2018
The 6th Antibody Industrial Symposium 2018 (AIS2018) will be held the 25th and 26th of June 2018 in Montpellier, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).
MAbSilico is selected to be accelerated at Le Château. March 2018
MAbSilico is talking at the Immunotherapies for Infectious Diseases Congress. December 2017
The second edition of the Immunotherapies for Infectious Diseases Congress - I4ID, that will be held in Lyon (France) on December 10-11, 2018, this year dedicated to Host-Directed Therapies (HDT) to fight infectious diseases.
MAbSilico is selected in the top 500 startups at the Hello Tomorrow Global Challenge. October 2017
The Hello Tomorrow Challenge is the world’s biggest early-stage startup competition for science and deep technology startups. Each year, they identify the best projects of the Challenge to attend the Hello Tomorrow Summit in Paris, an invite-only event bringing together the people that will change the world using science and technology around top investors in each sector, industrial leaders (Airbus, Google[x], Carrefour, Merck, Air Liquide, Facebook, etc.), international media (Bloomberg, BBC, Wired, etc.) and influencers (in 2016, Mike Bloomberg, Emmanuel Macron, CTO of Meta, CEO of Unity Biotech, etc).
MAbSilico is at the Next-Generation Antibodies and Protein Analysis. October 2017
Catalyzed by VIB’s Technology Scouting team, the Tools and Technologies meetings focus on the front end of innovation and bring together key innovators in selected life sciences research fields. The Next-Generation Antibodies and Protein Analysis conference, in Ghent (Belgium), is set to make another world class meeting, bringing together an exciting selection of top speakers and newly emerged companies. In addition to great scientific and technology program, the conference will provide ample networking opportunities.
MAbSilico received the "Bourse French Tech" from Bpifrance. October 2017
MAbSilico is founded. September 2017
We are happy to announce the incorporation of MAbSilico.